Dr. Reddy's Laboratories launches generic Zyprexa in the US

28 Oct 2011 Evaluate

Dr. Reddy's Laboratories and Teva Pharmaceutical Industries have commenced the commercial launch of Olanzapine Tablets, the generic version of Eli Lilly's Zyprexa. Based on IMS sales data, annual sales of Zyprexa were approximately $3.2 billion in the United States as of September 2011.

Teva's Olanzapine tablets in 2.5 mg, 5 mg, 7.5 mg, 10 mg and 15 mg and Dr. Reddy's Olanzapina tablets in 20 mg have each been awarded a 180-day period of marketing exclusivity in the US Dr. Reddy's is supplying the 20 mg version of the product following an April 2011 commercialization, manufacture and supply agreement with Teva. In addition, as per the terms of the agreement, Dr. Reddy's will launch their 2.5 mg, 5 mg, 7.5 mg, 10 mg ,15 mg and 20 mg of Olanzapine tablets upon expiration of the 180-day exclusivity period.

Dr. Reddy's Laboratories is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1342.45 16.45 (1.24%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.